Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05996185 · ClinicalTrials.gov registry record · Phase 2
Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
A Phase 2 study of T-Cell Lymphoma, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 2
- Study locations
NCT05996185: Recruiting Phase 2 study of T-Cell Lymphoma, sponsored by Yale University.
NCT05996185 is a Phase 2 study of T-Cell Lymphoma that is actively recruiting participants, run by Yale University. The registered enrollment target is 22 participants, below the 133-participant average among 15 other T-Cell Lymphoma trials with a reported enrollment target (83% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05996185, a Phase 2 study of T-Cell Lymphoma, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 2
- Study locations
Study Summary
Single-arm Phase II study evaluating the combination of mogamulizumab (MOGA) added on top of standard of care dose adjusted EPOCH (DA-EPOCH) or CHOEP in patients with newly diagnosed or relapsed/refractory (for CTCL only) aggressive T-cell lymphoma including patients with Adult T-cell leukemia/lymphoma (ATLL).
Primary Outcome
As assessed by the Lugano criteria for PTCL(16) and the global response score for CTCL(17)
Conditions Studied
Interventions
- DRUG Mogamulizumab
- DRUG DA-EPOCH Protocol
- DRUG CHOEP protocol
Study Locations (2)
Connecticut
- Yale Cancer Center, Clinical Trials Office - New Haven
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2024-10-09 |
| Est. Completion | 2027-11 |
| Phase | Phase 2 |
What NCT05996185 shows while recruiting
NCT05996185 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 133-participant average among 15 other T-Cell Lymphoma trials with a reported enrollment target (83% lower).
The record links to 1 condition, with T-Cell Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Mogamulizumab is the first listed.
NCT05996185 reports a single indexed study location in Connecticut, New York.
Frequently Asked Questions
What is clinical trial NCT05996185 about?
NCT05996185 is a clinical study titled "Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma". Single-arm Phase II study evaluating the combination of mogamulizumab (MOGA) added on top of standard of care dose adjusted EPOCH (DA-EPOCH) or CHOEP in patients with newly diagnosed or relapsed/refractory (for CTCL only) aggressive T-cell lymphoma including patients with Adult T-cell leukemia/lymph...
What is the current status of trial NCT05996185?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2024-10-09. Estimated completion is 2027-11.
What conditions does trial NCT05996185 study?
This clinical trial studies the following conditions: T-Cell Lymphoma.
What interventions are being tested in trial NCT05996185?
The interventions under investigation include: Mogamulizumab (DRUG), DA-EPOCH Protocol (DRUG), CHOEP protocol (DRUG).
Who is sponsoring clinical trial NCT05996185?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05996185 being conducted?
This trial has 2 study locations across Connecticut, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for T-Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05996185's enrollment target sits among peer trials
22 11th of 15 higher than 4 of 15 other T-Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other T-Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
RECRUITING · Phase 2
-
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
RECRUITING · Phase 2
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
-
A Study of Enasidenib in People With T-Cell Lymphoma
RECRUITING · Phase 2
-
Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas
ACTIVE NOT RECRUITING · Phase 2
-
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI